Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Improved drug regimen in patients with Graves' disease with suboptimal methimazole response
ChiCTR2200064060Phase 4Recruiting
- Sponsor
- Chinese PLA General Hospital
- Start
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of methimazole and levothyroxine sodium in Graves' disease (2 arms), sponsored by Chinese PLA General Hospital. Primary endpoints: thyrotrophin receptor antibody (TRAb), thyroid function and 1 more. Started Jul 2022; status: recruiting.
02
Drugs
methimazolelevothyroxine sodium
03
Conditions
Graves' disease
Beyond the preview
Go deeper on ChiCTR2200064060.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200064060.